Search Results
Dr Heymach on Updated AEGEAN Data in Resectable NSCLC
AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John Heymach
For NSCLC Neoadjuvant Adjuvant or Both
Neoadjuvant, Adjuvant, or Both: Individualized Perioperative Immunotherapy in Resectable NSCLC
Elevating Care in Resectable Stage I-III NSCLC
AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber
AACR 2023 highlights on advances in the treatment of hepatocellular carcinoma with Pierce Chow
Evolving landscape of IO therapy in NSCLC management leveraging the multi disciplinary approach
AACR 2023 highlights on advances in the treatment of biliary tract cancer with Robin Katie Kelley
July 25, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
The “Immunosurge” Continues: Expanding the Role of Immunotherapy in NSCLC
Clinical Investigator Perspectives in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
